Characteristic | Total | Breast cancer | p value | |
---|---|---|---|---|
Left-side BC | Right-side BC | |||
Number of patients | 94 | 51 (54.3%) | 43 (45.7%) | |
Age at 1st NCCT (years) | 53 (45–78) | 52 (45–74) | 55 (45–78) | 0.461 |
Age at 2nd NCCT (years) | 60 (48–80) | 60 (48–80) | 62 (48–79) | 0.371 |
NCCT interval (years) | 6.9 (1.0–12.6) | 6.8 (1.1–12.6) | 7.3 (1.0–11.7) | 0.664 |
Pathological stage | 0.292 | |||
0 | 2 (2.1%) | 0 (0.0%) | 2 (4.7%) | |
I | 13 (13.8%) | 9 (17.6%) | 4 (9.3%) | |
II | 28 (29.8%) | 15 (29.4%) | 13 (30.2%) | |
III | 47 (50.0%) | 26 (51.0%) | 21 (48.8%) | |
IV | 4 (4.3%) | 1 (2.0%) | 3 (7.0%) | |
Surgery | 0.952 | |||
BCS | 32 (34.0%) | 18 (35.3%) | 14 (32.6%) | |
Mastectomy | 62 (66.0%) | 33 (64.7%) | 29 (67.4%) | |
Chemotherapy | 0.882 | |||
Yes | 77 (81.9%) | 41 (80.4%) | 36 (83.7%) | |
No | 17 (18.1%) | 10 (19.6%) | 7 (16.3%) | |
Anthracycline or Taxane regimen | 0.699 | |||
Yes | 76 (80.9%) | 40 (78.4%) | 36 (83.7%) | |
No | 18 (19.1%) | 11 (21.6%) | 7 (16.3%) | |
Hormone therapy | 0.623 | |||
Yes | 71 (75.5%) | 37 (72.5%) | 34 (79.1%) | |
No | 23 (24.5%) | 14 (27.5%) | 9 (20.9%) | |
Targeted therapy (Trastuzumab) | 0.468 | |||
Yes | 5 (5.3%) | 4 (7.8%) | 1 (2.3%) | |
No | 89 (94.7%) | 47 (92.2%) | 42 (97.7%) | |
BMI (overweight) | 0.705 | |||
≧ 24 | 49 (52.1%) | 28 (54.9%) | 21 (48.8%) | |
  < 24 | 45 (47.9%) | 23 (45.1%) | 22 (51.2%) | |
BMI (obese) | 0.169 | |||
≧ 27 | 25 (26.6%) | 17 (33.3%) | 8 (18.6%) | |
  < 27 | 69 (73.4%) | 34 (66.7%) | 35 (81.4%) | |
Diabetes | 0.838 | |||
Yes | 15 (16.0%) | 8 (15.7%) | 7 (16.3%) | |
No | 79 (84.0%) | 43 (84.3%) | 36 (83.7%) | |
Hypertension | 0.180 | |||
Yes | 20 (21.3%) | 14 (27.5%) | 6 (14.0%) | |
No | 74 (78.7%) | 37 (72.5%) | 37 (86.0%) | |
Hyperlipidemia | 0.142 | |||
Yes | 13 (13.8%) | 10 (19.6%) | 3 (7.0%) | |
No | 81 (86.2%) | 41 (80.4%) | 40 (93.0%) |